U.S. Markets closed

Protara Therapeutics, Inc. (TARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.38-0.35 (-4.01%)
At close: 4:00PM EDT

Protara Therapeutics, Inc.

345 Park Avenue South
3rd Floor
New York, NY 10010
United States
646 844 0337
http://www.protaratx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Mr. Jesse SheffermanCo-Founder, CEO, Pres & Director379.08kN/A1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.Chief Scientific Operations Officer306.59kN/A1981
Mr. Blaine T. DavisCFO, Principal Financial & Accounting Officer and Sec.N/AN/A1974
Dr. Martin Sebastian Olivo M.D.Chief Medical OfficerN/AN/A1976
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Corporate Governance

Protara Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.